Literature DB >> 27881506

Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspective.

Milton Packer1.   

Abstract

Traditional approaches to the assessment of new treatments for heart failure have generally evaluated individual components of the syndrome at fixed points in time or have relied on surrogate physiological measures that are poorly correlated with the clinical status of patients. Conventional time-to-event trials that focus on morbidity and mortality represent an important methodological advance, but they generally assign undue weight to clinical events of less importance and are insensitive to difference in functional capacity among individuals who do not experience a clinical event during follow-up. Twenty years ago, a hierarchical clinical composite was developed to address these limitations; it aims to assess the clinical course of patients as a physician would in practice by combining a symptomatic assessment of the patient at each visit with an evaluation of the clinical stability of the patient between visits. The composite does not generate a numeric score by summing arbitrarily assigned weights to certain symptoms or events; instead, the composite ranks relevant measures and outcomes according to clinical priority. In doing so, the clinical composite minimizes the biases created by noncompleting patients in the assessment of symptoms or exercise tolerance while expanding the range of patients who contribute to the treatment difference in a typical morbidity and mortality trial. When applied appropriately, the hierarchical clinical composite end point has reliably distinguished effective from ineffective treatments. The composite may have particular advantages in the evaluation of new devices and transcatheter interventions in chronic heart failure and of new drugs for acute heart failure. Recent modifications enhance its discriminant characteristics and its ability to accurately assess the efficacy of novel interventions for heart failure.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  clinical trial [publication type]; heart failure

Mesh:

Year:  2016        PMID: 27881506     DOI: 10.1161/CIRCULATIONAHA.116.023538

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

1.  Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

Authors:  Keith M Sullivan; Ellen A Goldmuntz; Lynette Keyes-Elstein; Peter A McSweeney; Ashley Pinckney; Beverly Welch; Maureen D Mayes; Richard A Nash; Leslie J Crofford; Barry Eggleston; Sharon Castina; Linda M Griffith; Julia S Goldstein; Dennis Wallace; Oana Craciunescu; Dinesh Khanna; Rodney J Folz; Jonathan Goldin; E William St Clair; James R Seibold; Kristine Phillips; Shin Mineishi; Robert W Simms; Karen Ballen; Mark H Wener; George E Georges; Shelly Heimfeld; Chitra Hosing; Stephen Forman; Suzanne Kafaja; Richard M Silver; Leroy Griffing; Jan Storek; Sharon LeClercq; Richard Brasington; Mary E Csuka; Christopher Bredeson; Carolyn Keever-Taylor; Robyn T Domsic; M Bashar Kahaleh; Thomas Medsger; Daniel E Furst
Journal:  N Engl J Med       Date:  2018-01-04       Impact factor: 91.245

2.  Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial.

Authors:  Samvel B Gasparyan; Joan Buenconsejo; Elaine K Kowalewski; Jan Oscarsson; Olof F Bengtsson; Russell Esterline; Gary G Koch; Otavio Berwanger; Mikhail N Kosiborod
Journal:  Ther Innov Regul Sci       Date:  2022-06-14       Impact factor: 1.337

Review 3.  Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure.

Authors:  Stephen J Greene; Robert J Mentz; Mona Fiuzat; Javed Butler; Scott D Solomon; Andrew P Ambrosy; Cyrus Mehta; John R Teerlink; Faiez Zannad; Christopher M O'Connor
Journal:  Circulation       Date:  2018-09-04       Impact factor: 29.690

4.  Pilot study using 3D-longitudinal strain computation in a multi-parametric approach for best selecting responders to cardiac resynchronization therapy.

Authors:  Maxime Fournet; Anne Bernard; Sylvestre Marechaux; Elena Galli; Raphael Martins; Philippe Mabo; J Claude Daubert; Christophe Leclercq; Alfredo Hernandez; Erwan Donal
Journal:  Cardiovasc Ultrasound       Date:  2017-06-17       Impact factor: 2.062

5.  Secondary mitral regurgitation: reducing the leak, expanding the science.

Authors:  Sam Straw; Dominik Schlosshan; Klaus K Witte
Journal:  ESC Heart Fail       Date:  2020-10-05

Review 6.  Endpoints in Heart Failure Drug Development.

Authors:  Aliza Hussain; Arunima Misra; Biykem Bozkurt
Journal:  Card Fail Rev       Date:  2022-01-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.